



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية



شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد اعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيداً عن الغبار

في درجة حرارة من 15 – 20 مئوية ورطوبة نسبية من 20-40 %

To be kept away from dust in dry cool place of
15 – 25c and relative humidity 20-40 %



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل

**Study The Effect of Oral Corticosteroid
On Bronchial Hyperresponsiveness
In patients with Chronic Obstructive
Pulmonary Diseases**

THESIS

*Submitted for the partial fulfillment
of the Master Degree in Chest Diseases*

By

Mustafa Mohamed Saleh Farhan
M.B., B. CH.

Faculty of Medicine - Aden University

Supervised By

Prof. Tarek Safwat

Professor of Chest Diseases
Head of Chest Department

Faculty of Medicine - Ain Shams University

Dr. Laila Ashour

Assist. Professor of Chest Diseases

Faculty of Medicine - Ain Shams University

Dr. Gamal Abdel Rahman

Lecturer of Chest Diseases

Faculty of Medicine - Ain Shams University

Faculty of Medicine - Ain Shams University

2000

Handwritten signature in blue ink, possibly "Tarek Safwat".

Handwritten signature in blue ink, possibly "Laila Ashour".

Handwritten signature in blue ink, possibly "Mustafa Mohamed Saleh Farhan".

Handwritten signature in blue ink, possibly "Gamal Abdel Rahman".

Handwritten signature in blue ink, possibly "B 9214".



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

(سورة البقرة الآية ٣٢)

Acknowledgment

I thank God who granted me the ability to complete the work of this study.

*I would like to express my supreme gratitude to **Prof. Dr., Tarek Safwat**, Chairman and Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his continuous guidance, his close supervision, criticism and valuable instructions throughout this study.*

*It is a pleasure to express my gratitude and great appreciation to **Dr., Lila Ashour**, Assistant Professor of Chest diseases, Faculty of Medicine, Ain Shams University, for the time and effort she devoted to the supervision of the present work, her fruitful support, valuable instructions and encouragement throughout this study.*

*I would like also to express my deep thanks and supreme gratitude to **Dr., Gamal Abdel-Rahman**, Lecturer of Chest diseases, Faculty of Medicine, Ain Shams University, for his continuous guidance, and helpful supervision all through this work.*

I am also deeply thankful to all the staff of the Chest Department, Ain Shams University, for their cooperation and encouragement.

Mustafa Mohamed Saleh

2001



TABLE OF CONTENTS

• Introduction.....	1
• Aim of the Work.....	2
• Review of literature.....	3
• Definitions.....	3
• Epidemology.....	8
• Risk factors for C.O.P.D.....	10
• Natural history of C.O.P.D.....	20
• Pathology.....	22
• Clinical features.....	30
• Investigations.....	33
• Staging.....	49
• Treatment.....	51
• Patients and Methods.....	73
• Results.....	77
• Discussion.....	89
• Summary.....	95
• Conclusion.....	99
• Recommendation.....	101
• References.....	103
• Arabic Summary.....	

LIST OF ABBREVIATIONS

C.O.P.D	Chronic Obstructive Pulmonary Disease
FEV₁	Forced Expiratory Volume in one second
FEV₁/FVC	Forced Expiratory Volume in one second/Forced Vital Capacity
AAT	Alpha 1-antitrypsin
IgE	Immunoglobulin E
IgA	Immunoglobulin A
VC	Vital Capacity
RV	Residual Volume
V/Q	Ventilation/Perfusion ratio
FRC	Functional Residual Capacity
PEEPi	Intrinsic Positive End-Expiratory Pressure
CT	Computed Tomography
PEFR	Peak Expiratory Flow Rate
ABG	Arterial Blood Gases
REM	Rapid Eye Movement
MDI	Metered-Dose Inhaer
ACE	Angiotensin-Converting Enzyme
LTOT	Long Term Oxygen Therapy
CPAP	Continuos Positive Airway Pressure
BiPAP	Bilevel Positive Airway Pressure
FEF_{25-75%}	Average flow rate between 25% and 75% of FVC
FVC	Forced Vital Capacity

LIST OF TABLES

Table No.	Title	Page
Tab. 1	Risk factors for C.O.P.D.	19
Tab. 2	Severity of COPD Based on FEV1.	37
Tab. 3	Investigations for diagnosis and initial assessment.	46
Tab. 4	Diagnosis of COPD.	47
Tab. 5	Factors related to reduced survival in COPD.	50
Tab. 6	Step by step pharmacologic therapy for COPD.	64
Tab. 7	Indicators for long term oxygen therapy.	66
Tab. 8	Comparison of spirometric functions between those receiving oral prednisolone (Group I) and those receiving placebo (Group II) at the base line.	77
Tab. 9	Comparison of spirometric function tests before administration of oral predensolon and after 2 weeks of starting treatment (Group I).	78
Tab. 10	Comparison of spirometric function tests before administration of oral placebo and after 2 weeks of starting treatment (Group II).	80
Tab. 11	Percentage changes of spirometric functions after 2 weeks of starting treatment (GroupI).	82
Tab. 12	Percentage changes of spirometric functions after 2 weeks of starting treatment (GroupII).	83
Tab. 13	Comparison between percentage changes in spirometric functions between group I and group II after 2 weeks of starting treatment with prednisolon or placebo respectively.	84

